22 October 2020
The launch of Lancet Child and Adolescent Health Commission - the first ever to address paediatric pain - aims to raise the profile of children’s pain from early years to early adulthood.
11 October 2020
Professor Paul Riley will lead the scientific vision of the first institute of its kind in the world to physically merge the disciplines of developmental biology and regenerative medicine in a common goal to treat some of the world’s most prolific diseases.
23 September 2020
Public trust is key to a successful immunisation programme, writes Samantha Vanderslott in a piece for The Conversation.
18 August 2020
In an opinion piece for The Guardian, Professor Matthew Snape discusses the initial results of his team's antibody study in the context of coronavirus risk to school children.
12 August 2020
Oligonucleotides - short DNA or RNA molecules - have great therapeutic application for a range of diseases. Yet, their potential has not been fully unleashed because of challenges linked to efficient delivery. Read more to find out about recent developments in oligonucleotide modifications, and the platforms that may be used to deliver them to target sites.
27 July 2020
Congratulations to Professor Andrew Pollard who is the Winner of the Policy Engagement category in the Vice-Chancellor Innovation Awards 2020 for his work on Global policy on typhoid vaccines through research at Oxford!
20 July 2020
A team of scientists at Oxford Vaccine Group (Department of Paediatrics) and Oxford University’s Jenner Institute has taken the next step towards the discovery of a safe, effective and accessible vaccine against coronavirus.
2 July 2020
The European Commission has granted Marketing Authorisation to Janssen for a new Ebola vaccine, developed in partnership with the University of Oxford.
26 June 2020
The Duke of Cambridge visits the University of Oxford’s Oxford Vaccine Centre, to learn more about their work to establish a viable vaccine against COVID-19.
AstraZeneca to supply Europe with up to 400 million doses of Oxford University’s vaccine at no profit
15 June 2020
AstraZeneca has reached an agreement with Europe’s Inclusive Vaccines Alliance (IVA), spearheaded by Germany, France, Italy and the Netherlands, to supply up to 400 million doses of the University of Oxford’s COVID-19 vaccine, with deliveries starting by the end of 2020.
15 June 2020
Bristol Science Film Festival awarded the Professional Science Fact Film Prize to "The Adventures of Alice in Typhoidland" co-created by the Oxford Vaccine Group.
1 June 2020
Stéphane Paulus and Else Bijker explore the topic in their article for The Conversation.
22 May 2020
Oxford Vaccine Group researchers have begun recruiting for the next phase in human trials of a COVID-19 vaccine in human volunteers.
13 May 2020
The Academy of Medical Sciences, the independent body in the UK representing the diversity of medical science, has announced the election of fifty new Fellows, including Professor Matthew Wood from the Department of Paediatrics.
12 May 2020
How can researching a cohort of infants from KwaZulu-Natal in South Africa help explain differing HIV susceptibility of males and females? Professor Philip Goulder, head of the HIV Research Group, discusses the Baby Cure study.
30 April 2020
The University of Oxford has today announced an agreement with the UK-based global biopharmaceutical company AstraZeneca for the further development, large-scale manufacture and potential distribution of the COVID-19 vaccine candidate currently being trialled by the Oxford Vaccine Group.
24 April 2020
University of Oxford researchers have begun testing a COVID-19 vaccine in human volunteers in Oxford today. Around 1,110 people will take part in the trial, half receiving the vaccine and the other half (the control group) receiving a widely available meningitis vaccine.
Paediatrics project receives funding to assess novel coronavirus infection rates in children and teenagers across the UK
20 April 2020
A multi-site project, called ‘What’s the STORY?’ has received funding from UK Research and Innovation (UKRI) to assess novel coronavirus infection rates in children and teenagers across the UK. Given the importance of this study to the national Covid-19 response it has been deemed a priority study for the National Institute for Health Research’s (NIHR) Urgent Public Health Response.
Funding for new COVID-19 studies awarded to OVG's project on infectious disease immunity in children
17 April 2020
Five projects from across Oxford University's Medical Sciences Division, including a project led by Professor Matthew Snape from the Oxford Vaccine Group, are among twenty-one new studies into the novel coronavirus which have been funded by the UK government.